Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sorin Group, a medical technology company, has announced the commercial market release and first implant of its new-generation Paradym CRT 8750 cardiac resynchronization therapy defibrillator.
Subscribe to our email newsletter
Together with the new SITUS BW 28D left ventricle pacing lead and lead delivery system, Paradym CRT forms a complete new CRT system for heart failure patients, the company said.
Paradym CRT is said to be designed to allow more flexibility in the management of cardiac resynchronization and anti-tachyarrhythmia therapy in heart failure patients, due to the unique Brady-Tachy Overlap (BTO) feature.
Fred Hrkac, president of the CRM business unit at Sorin Group, said: “Sorin Group is delighted to announce the launch of Paradym CRT. The device provides patients the highest delivered energy available on the market to date in a 34cc small and long-lasting device. With Paradym CRT, patients have the opportunity to exercise, while arrhythmias at all different rates can be accurately treated.
“Paradym CRT is the first device of a novel Sorin Group platform which will bring a wide range of treatment options for physicians and patients, further strengthening our innovative leadership in the hemodynamic management of heart failure.”